Triptan use as a function of cardiovascular risk. A population-based study: Research submission

Headache

Volumn 50, Issue 2, 2010, Pages 256-263

  Bigal, Marcelo E ^a,b   Golden, Wendy ^c   Buse, Dawn ^b   Chen, Ya Ting ^c   Lipton, Richard B ^b,d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Merck   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Migraine; Triptan

Indexed keywords

ANTIMIGRAINE AGENT; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; TRIPTAN DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISABILITY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; FEMALE; HEADACHE; HEALTH SURVEY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; POPULATION RISK; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; UNITED STATES; VASOCONSTRICTION;

ADOLESCENT; ADULT; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS; DISABILITY EVALUATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MIGRAINE DISORDERS; MYOCARDIAL INFARCTION; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING; STROKE; THORACIC SURGERY; TRYPTAMINES; YOUNG ADULT;

EID: 75849163031     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2009.01595.x     Document Type: Article

References (43)

1. Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. Cmaj. 1997 156: 1273 1287.
2. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 55: 754 762.
3. Hargreaves RJ. Pharmacology and potential mechanisms of action of rizatriptan. Cephalalgia. 2000 20 (Suppl. 1 2 9.
4. Goadsby PJ, Hargreaves RJ. Mechanisms of action of serotonin 5-HT1B/D agonists: Insights into migraine pathophysiology using rizatriptan. Neurology. 2000 55 9 Suppl. 2 S8 14.
5. Golden WM, Bigal ME, Yu J, et al. Impact of cardiovascular disease and cardiovascular risk on the treatment of migraine. Am J Med. 2009 in press.
6. Kolodner K, Lipton RB, Lafata JE, et al. Pharmacy and medical claims data identified migraine sufferers with high specificity but modest sensitivity. J Clin Epidemiol. 2004 57: 962 972.
7. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 68: 343 349.
8. Bigal ME, Kurth T, Santanello N, et al. Migraine and cardiovascular disease in the population. The American Migraine Prevalence and Prevention Study. Neurology. 2009 in press.
9. Stewart WFRM, Bigal ME, Lipton RB. Lifetime migraine incidence. Results from the American Migraine Prevalence and Prevention study. Headache. 2005 46: 52.
10. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention study. Headache. 2007 47: 355 363.
11. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: Results from the American Migraine Study. Headache. 1998 38: 87 96.
12. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001 41: 646 657.
13. HCSotIH Society. The International Classification of Headache Disorders. 2nd Edition. Cephalalgia. 2004 24 (Suppl. 1 1 149.
14. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000 88: 41 52.
15. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology. 2008 71: 559 566.
16. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA. 2006 296: 283 291.
17. Kurth T, Gaziano JM, Cook NR, et al. Migraine and risk of cardiovascular disease in men. Arch Intern Med. 2007 167: 795 801. (Pubitemid 46658337)
18. Lipton RB, Bigal ME, Stewart WF. Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology. 2005 65 12 Suppl. 4 S50 S58.
19. Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology. 2000 55 9 Suppl. 2 S29 S35.
20. Dowson A, Jagger S. The UK migraine patient survey: Quality of life and treatment. Curr Med Res Opin. 1999 15: 241 253.
21. Garcia ML, Baos V, Lainez M, Pascual J, Lopez-Gil A. Responsiveness of migraine-ACT and MIDAS questionnaires for assessing migraine therapy. Headache. 2008 48: 1349 1355.
22. Pascual J, Lainez MJ, Baos V, Garcia ML, Lopez-Gil A. Predictive model for the Migraine-ACT questionnaire in primary care. Curr Med Res Opin. 2007 23: 3033 3039.
23. Lipton RB, Amatniek JC, Ferrari MD, Gross M. Migraine Identifying and removing barriers to care. Neurology. 1994 44 6 Suppl. 4 S63 S68.
24. Bigal M, Krymchantowski AV, Lipton RB. Barriers to satisfactory migraine outcomes. What have we learned, where do we stand? Headache. 2009.
25. Sheftell FD, Tepper SJ, Bigal ME. Migraine: Barriers for care. Neurol Sci. 2005 26 (Suppl. 2 s140 s142.
26. Wenzel R, Dortch M, Cady R, Lofland JH, Diamond S. Migraine headache misconceptions: Barriers to effective care. Pharmacotherapy. 2004 24: 638 648.
27. Edvinsson L, Uddman E, Wackenfors A, Davenport A, Longmore J, Malmsjo M. Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: Relationship to clinical effect. Clin Sci (Lond). 2005 109: 335 342.
28. Nilsson T, Longmore J, Shaw D, et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol. 1999 372: 49 56.
29. Evers S, Husstedt IW, Enbergs A. Coronary angiography in migraine patient after subcutaneous sumatriptan. Lancet. 1995 345: 198.
30. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992 267: 64 69.
31. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia. 2003 23: 519 527.
32. Orlando LA, Matchar DB. When to stress over triptans: A Markov analysis of cardiovascular risk in migraine treatment. Headache. 2004 44: 652 660.
33. Scary E. The Body in Pain: The Making and Unmaking of the World, First edn. New York: Oxford University Press 2001.
34. Kurth T. Associations between migraine and cardiovascular disease. Expert Rev Neurother. 2007 7: 1097 1104.
35. Kurth T. Migraine with aura and ischemic stroke: Which additional factors matter? Stroke. 2007 38: 2407 2408.
36. Wayne VS. A possible relationship between migraine and coronary artery spasm. Aust N Z J Med. 1986 16: 708 710.
37. Rose KM, Carson AP, Sanford CP, et al. Migraine and other headaches: Associations with Rose angina and coronary heart disease. Neurology. 2004 63: 2233 2239.
38. Scher AI, Terwindt GM, Picavet HS, Verschuren WM, Ferrari MD, Launer LJ. Cardiovascular risk factors and migraine: The GEM population-based study. Neurology. 2005 64: 614 620.
39. Scher AI, Terwindt GM, Verschuren WM, et al. Migraine and MTHFR C677T genotype in a population-based sample. Ann Neurol. 2006 59: 372 375.
40. Martelletti P, Haimanot RT, Lainez MJ, et al. The Global Campaign (GC) to Reduce the Burden of Headache Worldwide. The International Team for Specialist Education (ITSE). J Headache Pain. 2005 6: 261 263.
41. Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen ovale and migraine: A quantitative systematic review. Cephalalgia. 2008 28: 531 540.
42. D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation. 2008 117: 743 753.
43. Kurth T, Slomke MA, Kase CS, et al. Migraine, headache, and the risk of stroke in women: A prospective study. Neurology. 2005 64: 1020 1026. (Pubitemid 40388455)